

Sotrovimab : Community treatment of SARS COV2 infection for patients in receipt of Haemodialysis

Sotrovimab (neutralising monoclonal Abs (nmAb)) is indicated for in-community treatment of SARS COV2 for patients in receipt of haemodialysis - they are deemed highly clinically vulnerable.

Eligible patient are those within 5 days of symptom onset, ongoing symptoms, AND within 5 days of a positive PCR test.

If symptoms have resolved, or are resolving, or patient had no symptoms then treatment is not required.

Please direct eligible patients to the contact number (0300 790 6769) advertised on NHS Inform where they will be triaged by the flow centre.

They should have received this information by letter from PHS (Public Health Scotland).

Ask the patient to inform the person triaging them that they are a dialysis patient and when their next dialysis session is due to take place.

The flow centre refers appropriate patients to OPAT for treatment – ideally noting that they are a dialysis patient. OPAT will check eligibility - it should be clear from TRAK +/- discussion with the patient that they are a dialysis patient.

OPAT will flag the patient up to renal consultant on call.

It is important to ask the patient to use the contact number in order to ensure all patients are correctly recorded.

Liaison with WGH OPAT if needed should be via WGH.InfectiousDiseases@nhslothian.scot.nhs.uk

HOW and WHERE TO ADMINISTER SOTROVIMAB

Dialysis must take place in isolation (single room) in the circumstance of a positive SARS COV2 PCR test.

Sotrovimab should be administered at the end of the next routine dialysis session that is due.

If possible this should be accommodated in a single room in the WGH dialysis unit to allow for isolation and to facilitate provision of Sotrovimab.

[WGH Dialysis Unit Ext 31879 / 32566]

- The treatment with Sotrovimab must be documented on Trak.
Use the Back slash code: \sotrovid[space]
- Sotrovimab must be prescribed on Vital Data to allow administration by dialysis unit staff.
(Use free text 'comment on starting box' to enter drug name until coded entry available)
- Sotrovimab is given as a single infusion of 500mg in 100ml NaCl 0.9% over 30 minutes at the end of dialysis via a needle retained in the fistula for this purpose or via the central line.
- Please then email GP practice 'clinical GP *name of practice*' to inform them of administration.